Christopher J. Sweeney

Christopher Sweeney (University of Adelaide; formerly Dana-Farber) was principal investigator of CHAARTED, the ECOG trial showing early docetaxel with androgen deprivation adds more than a year of survival in high-volume metastatic hormone-sensitive prostate cancer, and co-led ENZAMET (enzalutamide) with ANZUP. His work established treatment intensification at diagnosis as the standard approach. He now directs an immunogenomics institute in South Australia.